Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 4Urologic Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Hemorrhage 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Advanced Ovarian Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 6Paclitaxel 5Carboplatin 4Bevacizumab 3oregovomab 2Nivolumab 2Hyperthermic Intraperitoneal Chemotherapy 2Cisplatin 2tislelizumab 1spartalizumab 1rucaparib 1olaparib 1niraparib 1lenvatinib 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1anlotinib 1Surveys and Questionnaires 1Saline Solution 1Ramucirumab 1Platinum 1Nutrition Assessment 1Neoadjuvant Therapy 1Leucovorin 1Irinotecan 1Immunotherapy, Adoptive 1Glucose 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Ovarian Epithelial × Saline Solution × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡